RF Microneedling Boca Raton: What the FDA Clearance Actually Covers

Almost every page selling RF microneedling Boca Raton patients will read describes the device as approved for skin tightening. The clearance documents say something quite different, and in October 2025 the FDA published a safety communication of its own. Both are public, both are short, and reading them changes how you choose a provider.

What RF microneedling devices are actually cleared to do

There are two separate regulatory routes here, and the distinction is the root of most of the confusion.

Plain mechanical microneedling devices, with no radiofrequency, sit under product code QAI as Class II devices. For those, the FDA states plainly what it has authorised: “The FDA has legally authorized microneedling devices to improve the appearance of facial acne scars, facial wrinkles, and abdominal scars in patients aged 22 years or older.” That is a real cosmetic authorisation, and it is narrow.

Radiofrequency microneedling devices take a different route entirely. They are regulated as electrosurgical devices under 21 CFR 878.4400, product code GEI, and their cleared indications are about coagulating tissue and stopping bleeding.

Read those three rows again and notice what is missing. No wrinkles. No tightening. No collagen. No rejuvenation. The treatment can still be worth having — the clinical literature below is reasonably encouraging — but a clinic telling you the device is approved for skin tightening is describing a document that does not exist.

Why the FDA calls this a medical procedure

On 15 October 2025 the FDA published Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling. It is the most important document in this category, and the line in it that should decide where you have this done is worth quoting directly: “RF microneedling is a medical procedure, not a cosmetic treatment, and these devices should not be used at home.”

The agency asks patients to seek care from a licensed health care provider with training and experience on the device being used, and asks providers to watch how a treatment is actually going rather than run a fixed protocol on every face. Read as guidance, it is about who, not about whether.

That is because the settings which make this treatment work are the same settings that make it a medical one. Needle depth, energy, pulse duration and the number of passes are chosen against your anatomy, and the temple, the lower eyelid and the jawline do not behave like the cheek. The difference between a good result and a mediocre one is settings, anatomy and judgement, which is to say it is the person holding the handpiece.

What the published evidence supports, and how confident it is

The most recent systematic review of radiofrequency for facial rejuvenation pooled 15 studies and 1,230 participants — but only one was a randomised controlled trial, and eleven were case series. That shape matters more than any single percentage.

Its reported outcomes: skin texture improved in 71–100% of patients across four studies; patient satisfaction ran 82–100% across thirteen studies, with the largest, at 745 participants, recording 93.2% satisfied. Pain was low, a mean of 1.94 out of 10. Across nine studies and 912 patients there were no serious or permanent complications reported.

The honest part is how the authors graded their own confidence. Using GRADE-CERQual they rated aesthetic outcomes, satisfaction and safety as moderate confidence, firmness as low to moderate, and lifting and tone improvement as low confidence. They also wrote that the predominance of favourable results “indicates a likely influence of selective reporting and publication bias,” and noted that not one of the fifteen studies measured downtime.

For acne scarring specifically, a 2025 systematic review of 16 studies and 481 patients concluded that fractional RF microneedling is “likely an effective treatment… when used as a monotherapy,” and that randomised trials are still needed to establish parameters. Note the hedge; it is the authors’, not ours.

Skin type: a genuine tension in the record

Two primary sources point in different directions, and a page that only quoted one of them would be selling you something.

The clearance restricts Morpheus8 above 62 mJ/pin to Fitzpatrick I–IV. Against that, a critical review in Dermatologic Surgery covering 42 higher-quality studies concluded that RF microneedling “can be used repeatedly and safely in combination with other treatment modalities and in individuals with darker skin phototypes,” and that its dermal remodelling is “slow and progressive but continue[s] to improve even 6 months after treatment.”

Both are true statements about different things: one is a labelling limit tied to an energy threshold, the other is a clinical-literature conclusion about the modality. The practical reading is that darker phototypes are treatable, that energy selection is where the risk sits, and that the recent systematic review performed no analysis stratified by Fitzpatrick type at all. We could find no published table of post-inflammatory hyperpigmentation rates by skin type specific to this treatment. That gap is real, and it argues for conservative settings and a test area rather than for confidence.

Sessions and downtime: what is established and what is not

Three-session protocols are described as commonly employed, and the dose-response study used one to three sessions four to twelve weeks apart. That is the honest extent of it. No primary source establishes a required or optimal number, and the acne-scar review states directly that trials are still needed “to establish appropriate treatment parameters.”

Downtime is worse served by the literature. The systematic review’s authors identified it as a major evidence gap, having found that not a single one of their fifteen studies quantified it. What is documented, from a combination study of 26 patients, is that “all patients resumed normal activities within 7 days of treatment,” with erythema, oedema and swelling in between.

Reported adverse effects across the pooled studies were erythema in 17.6–100% of patients and oedema in 5.3–26.5%, alongside bruising and occasional small vesicles. Those are the ordinary experiences. The FDA safety communication describes the uncommon ones, and the gap between the two is mostly technique.

If you want the same evidence-first treatment of injectables, the Botox and Dysport page and the dermal fillers page are built the same way, and the full list is on the skin and laser section of our services page.

Frequently asked questions

Sources and how this page was built

Device indications were read from the FDA 510(k) summaries named below on 26 September 2026, and are quoted as cleared. The safety communication is quoted from the FDA page as published. Clinical figures are taken from the systematic reviews cited, with the authors’ own confidence ratings and limitations reported alongside them. Where a widely repeated claim could not be traced to a primary record — collagen percentages, fixed session counts, downtime figures — it is named as untraceable rather than repeated.

Why patients choose Brazelia MedSpa

The FDA has now said in writing that this is a medical procedure rather than a cosmetic one. That single sentence is the case for having it done somewhere with physicians on the premises, and it is the reason this page leads with the clearance text instead of a before-and-after gallery.

Energy settings are what this treatment turns on, and they are chosen against a face rather than read off a protocol sheet. RF microneedling in Boca Raton is performed here by Khali Reed, CRNA, APRN, who assesses the skin, the anatomy and the energy before anything is switched on, and who will say when a lower setting or a different treatment is the better answer.

Energy devices are the part of aesthetics where the operator matters most, and the professional societies are unambiguous about it: the American Society for Dermatologic Surgery Association calls for “on-site physician supervision of all non-physicians performing medical procedures,” and opposes “in-name-only medical directors.” Brazelia MedSpa is physician-directed, on site, with Dr. Herbert R. Slavin, MD as medical director rather than a name on a licence.

Brazelia MedSpa has treated patients from the same address in downtown Boca Raton for 18 years, near Mizner Park, and serves patients across South Florida, from Delray Beach and Boynton Beach to Deerfield Beach and Fort Lauderdale. In a field where med spas open and close within a season, staying in one place that long is its own kind of evidence. Patients rate the practice 4.5 out of 5 across 24 Google reviews.

A face is also rarely treated as just a face here. Because Brazelia MedSpa runs hormone, metabolic, skin and regenerative programmes under one roof, a treatment plan can take account of what else is going on — skin quality, weight change, hormonal shifts — instead of being sold in isolation. Where that is relevant to you it comes up at the consultation. Where it is not, nobody raises it.

New patients start with a consultation, and nothing is treated on a first visit unless you want it to be. You will hear what the approved labelling actually supports before you hear what it costs.

This page describes what published labels, regulatory records and peer-reviewed research report about these treatments. It is general health information, not medical advice, and it is not a substitute for a consultation. Whether any treatment is appropriate for you is a clinical judgement that depends on your history and examination.